Taiwan Petar Vazharov, CEO of Lotus Pharmaceuticals, is a medical doctor with an MBA who joined Alvogen in 2009 as one of its first international hires. After building the company’s Central and Eastern European business, he spent the past decade transforming Lotus – driving seven consecutive years of double-digit growth, expanding…
Taiwan Dr. I-Shu Lee, founder and CEO of Vitae Biomedical, began his career as a postdoctoral researcher before making the uncommon leap from academic laboratory to entrepreneurship in 2019. Built around a proprietary urine-based protein detection technology for early cancer screening, Vitae Biomedical has already achieved commercial traction in Taiwan, partnering…
Taiwan Honeybear Biosciences is emerging as a pioneering force in precision oncology, leveraging its proprietary CoNectar glycan conjugation platform to advance next-generation ADCs and ARCs. Guided by a globally experienced leadership team and supported by strategic partnerships across Asia and beyond, the Taiwan-based biotech is progressing innovative theranostic programmes towards clinical…
Taiwan Fu Feng Kuo, founder and chief executive of Jyong Biotech and its operational subsidiary Health Ever Biotech, outlines the company’s two-decade journey from botanical raw materials into a NASDAQ-listed pharmaceutical developer. With a lead asset that has completed four Phase III clinical trials for benign prostatic hyperplasia, she makes the…
Taiwan Susan Liao, General Manager of Everest Pharmaceutical Industrial Co., Ltd., represents the second generation of the family business founded in 1978. Trained in pharmacy with a PhD in clinical medicine, she has spent nearly two decades at the company. Everest, with over 40 years of history, specialises in pellet-based drug…
Taiwan Jaw-Jou Kang, Professor at NYCU, former head of Taiwan’s Food and Drug Administration and current chair of the Taiwan Society of Regulatory Affairs for Medicinal Products discusses the nation’s regulatory transformation, challenges in talent retention, advances in regenerative medicine frameworks, and Taiwan’s positioning within the global biopharmaceutical ecosystem whilst navigating…
Taiwan Steve Kuo, Chairman of TRPMA, outlines Taiwan’s biotech strategy: strengthening clinical trial infrastructure, regulatory alignment and global partnerships. Drawing on experience across academia, government and diplomacy, he emphasises cultural change in trial participation and building a collaborative ecosystem, positioning Taiwan to compete globally, particularly in cell therapy and innovative drug…
Taiwan Hans Duijf, General Manager of Novo Nordisk Taiwan, has spent his entire 28-year career with the Danish pharmaceutical company, a rare tenure in today’s era of executive mobility. Duijf has led affiliates across several regions before arriving in Taiwan eight months ago. A committed advocate of the company’s triple bottom…
Taiwan Sen Kuei Yeh, Chairman of Ta Fong Pharmaceutical, is the second-generation leader of one of Taiwan’s established domestic manufacturers. Joining in the 1990s, he assumed leadership in 2016 after gaining experience across marketing and manufacturing. Under his stewardship, Ta Fong has expanded in generics and OTC products and developed Taiwan’s…
Taiwan Heidi Wang, recently retired CEO of OBI Pharma, transitioned from nearly three decades at Bristol-Myers Squibb (BMS) to lead the Taiwanese biotech for close to three years, aiming to advance global oncology therapeutics from Taiwan. She pivoted OBI from cancer vaccines to proprietary glycan-based GlycOBI® ADCs, with two Phase I…
Taiwan Joe Yeh describes founding aetherAI to digitise pathology and embed AI into routine diagnostics, addressing inefficiency, subjectivity, and missed disease detection. He explains Taiwan’s rapid adoption, a research-driven market access strategy, flexible pricing, and global expansion across Germany, Japan, and the US, positioning AI-driven pathology as foundational infrastructure for precision…
Taiwan Dr Long Sheng Fan, CEO, discusses Iridium Medical Technology’s development of a 4,000-pixel bionic retina. By leveraging Taiwan’s semiconductor expertise and AI convolution, the firm addresses retinal degeneration. Currently in clinical trials, the venture targets high-value medical markets, aiming to restore functional vision through sophisticated neural electronic interfaces and global…
See our Cookie Privacy Policy Here
